Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by ...

Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by 2035, representing a robust CAGR of 9.80%.Increasing prevalence of ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...

During 1Q25, the GS GQG Partners International Opportunities Fund outperformed the MSCI ACWI ex-USA (Net) benchmark. Click ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of scheming to delay a generic version of its schizophrenia drug Seroquel ...

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors’ attention.

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.

Eli Lilly LLY and AstraZeneca AZN are leading drugmakers with significant involvement in oncology, immunology, and the cardiometabolic disease space. Both are making substantial investments in ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

While trade talks with the U.S. are still underway, Indonesia must reassess its non-tariff measures to address U.S. concerns while ensuring fair trade practices and maintaining economic stability.